查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1136916

全球伤口护理生物製品市场-2022-2029

Global Wound Care Biologics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

伤口护理生物製剂市场的增长受到烧伤发病率上升、伤口护理生物製剂在损伤治疗中越来越多的采用、老年人口不断增加以及研发活动的推动。

糖尿病患病率上升预计将推动市场增长

预计糖尿病和烧伤等疾病发病率的上升将在预测期内提振市场。根据 2022 年 5 月发表在 Star Pearls 上的一篇文章，全球糖尿病足溃疡的年发病率在 910 万至 2610 万之间。大约 15-25% 的糖尿病患者在其一生中会患上糖尿病足溃疡。新诊断的糖尿病患者逐年增加，糖尿病足溃疡的发病率也在上升。糖尿病足溃疡最常见于 45 岁以上的糖尿病患者，但可发生在任何年龄。在糖尿病患者中，腿部和下背部的小血管发生严重的动脉硬化，引起血管紊乱，这也是糖尿病足部感染的原因之一。在糖尿病足感染中，伤口供血不足会减缓癒合并最终导致坏死和坏疽。由于这些疾病的增加，全球对用于伤口护理的生物製剂的需求正在增加。

此外，市场参与者正在采取各种策略，例如合作伙伴关係和产品发布。例如，2021 年 1 月，Integra Life Sciences 收购了 ACell, Inc.。此次收购使 Integra 能够提供更全面、更复杂的伤口管理解决方案。

高昂的伤口护理成本阻碍了市场增长

但是，预计所有伤口的医疗保健费用在 282 亿美元到 967 亿美元之间，包括感染控制费用，其中手术伤口和糖尿病溃疡是最昂贵的。此外，门诊费用（9.8-357 亿美元）高于住院费用（5.0-243 亿美元），这可能是由于门诊伤口护理的增加。这些因素限制了市场增长。

COVID-19 影响分析

COVID-19 的出现对全球伤口护理生物製剂市场产生了相当大的影响。通常，医护人员每周至少一次通过评估伤口进展、清创和应用 CTP（皮肤替代品）来治疗慢性伤口。医院门诊部的伤口诊所一直是治疗这些伤口的主要护理点。然而，这些设施中有许多在最初的 COVID-19 爆发期间关闭，导致许多患有慢性伤口的患者看不到或治疗较晚。这对伤口护理市场产生了负面影响。

由于正在进行的临床试验的延迟或取消、行业关闭以及政府法规将重点转移到控制冠状病毒疾病上，一些市场参与者正在放慢新疗法的开发。面临困难。

此外，市场参与者正在努力通过采用收购和新产品发布等市场策略来扩展业务。同样在 2020 年 11 月，史赛克公司收购了 Wright Medical Group N.V.，这是一家专注于四肢和生物製品的全球医疗器械公司。

全球伤口护理生物製品市场报告将提供对大约 65 多个市场数据表、65 多个图表和 200 多页（大约）的访问。

内容

第一章市场研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 烧伤发生率增加
      • 加大研发力度
    • 约束因素
      • 用于伤口护理的生物製剂成本高
    • 影响分析

第五章行业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析
  • 定价分析
  • 未满足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按产品类型

  • 活的皮肤替代品
    • 合成皮肤移植物
    • 沿着嫁接
    • 异种移植
  • 外部代理

第 8 章按伤口类型

  • 慢性伤口
    • 糖尿病足溃疡
    • 静脉性腿部溃疡
    • 压疮
  • 急性伤口
  • 手术伤口
  • 烧伤
  • 其他

第 9 章，最终用户

  • 医院
  • 燃烧中心
  • 门诊手术中心
  • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 按治疗类型划分的基准

第 12 章公司简介

  • Organogenesis Inc.
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Integra Lifesciences
  • Smith and Nephew
  • Acell Inc.
  • Osiris Therapeutics
  • Avita Medical
  • Solsys Medical
  • Generex Biotechnology
  • Mimedx
  • Skye Biologics

第 13 章全球伤口护理生物製品市场-DataM

简介目录
Product Code: DMMD742

Market Overview

Wound care biologics market size was valued at US$ xx million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 6.2% during the forecast period (2022-2029).

Wound care biologic therapies promote the re-establishment of the intrinsic repair mechanisms and application of these active biological agents, including plant-derived active biomolecules, which exhibit antimicrobial, antioxidant, or anti-inflammatory attributes. Biologic dressings help to prevent evaporative heat loss, water loss, protein and electrolyte loss, and contamination.

Market Dynamics

The wound care biologics market growth is driven by the rise in the incidence of burn injuries, the rising adoption of wound care biologics for treating injuries, the increase in the geriatric population, and research and development activities.

The rising prevalence of diabetes diseases is expected to drive the market growth

The rising incidence of diseases, such as diabetes and burn injuries, is expected to boost the market over the forecast period. As per the article published in Star Pearls in May 2022, the annual incidence of diabetic foot ulcers worldwide is between 9.1 to 26.1 million. Around 15 to 25% of patients with diabetes mellitus will develop a diabetic foot ulcer in their lifetime. As the number of newly diagnosed diabetics is increasing annually, the incidence of a diabetic foot ulcers is also bound to rise. Diabetic foot ulcers can arise at any age despite being most prevalent in ages 45 and over in patients with diabetes mellitus. Patients suffering from diabetes mellitus develop intense atherosclerosis of the small blood vessels in the legs and feet, directing to vascular compromise, which is another cause of diabetic foot infections. Healing is delayed, eventually leading to necrosis and gangrene because blood cannot reach the wound. The rising disease incidence leads to increasing demand for wound care biologics worldwide.

In addition, the market players are adopting different strategies, such as collaboration and product launches. For instance, in January 2021, Integra Lifesciences acquired ACell, Inc. This acquisition enabled Integra to deliver more comprehensive and complex wound management solutions.

The high cost of wound care will hamper the growth of the market

However, healthcare cost predictions for all wounds ranged from $28.2 to $96.7 billion, including costs for infection management, in which surgical wounds and diabetic ulcers were the most expensive to treat. Moreover, outpatient costs ($9.8-$35.7 billion) are higher than inpatient costs ($5.0-$24.3 billion), possibly due to increased outpatient wound treatments. These factors are limiting the market growth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global wound care biologics market. Mainly, healthcare professionals treat chronic wounds at least once a week to assess the progress of the wound, provide debridement or apply CTPs (skin substitutes). The hospital outpatient department wound clinics had the primary care site to treat these wounds. Still, with the closing of many of these facilities during the initial COVID-19 rise, many patients with chronic wounds were not seen or delaying treatment.. This negatively affected the wound care market.

Some market players have faced difficulties developing new treatments because of the delay or cancellation of ongoing clinical trials and government restrictions to shut down the industries or to move the focus on managing the coronavirus infection.

In addition, the market players were engaged in expanding the business by adopting the market strategies such as acquisition or new product launches. Also, in November 2020, Stryker Corporation acquired Wright Medical Group N.V., a global medical devices company concentrated on extremities and biologics.

Segment Analysis

The chronic wounds segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The chronic wounds segment is expected to boost the market over the forecast period. Chronic wounds construct significant problems for patients. They are hurting and tender. Wounds often fatigue and emit odors, and involved dressings are often evident. Unprotected by an unbroken skin envelope, these wounds can be retraumatized and improvement in size. They may design an infection directed to sepsis and amputation. Patients with diabetes and obesity are at increased risk of developing chronic wounds. The vast majority of people who have a long open wound usually also have other significant health conditions. The simultaneous presence of a variety of chronic diseases is called comorbidity. Chronic wounds are usually confused by comorbidities, making it challenging to track chronic wounds as a disease.

As per the Wound Infection Clinical Practice data in 2022, the Standard clinical microbiology laboratory released outcomes that only supply information regarding a small subset of the bacterial species present, mainly in chronic wounds. If infection with fungi, mycobacteria or anaerobic bacteria is presumed, for example, following environmental contamination of a wound, this should be precisely requested or concerned with a microbiologist as these organisms need further examinations and processing. The increasing incidence and advanced diagnostics for chronic wounds drive the wound care biologic market.

Geographical Analysis

North America region holds the largest market share of the global Wound Care Biologics market

North America dominates the market for wound care biologics and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to the increasing geriatric population, technological advancement, and growing research and development activities. According to the article published in Advance in Wound Care in May 2021, chronic wounds are mostly seen in the elderly. In the United States, 3% of the population aged 65 has open wounds. By 2060, the U.S. government evaluates that the elderly population will be over 77 million, signifying that chronic wounds will resume being an increasingly constant concern in these people. Around the United States, 2% of the entire population is assessed to be impacted by chronic wounds.

In addition, the market players are applying market strategies such as collaboration and new product launches. For instance, in June 2021, MIMEDX received approval from the Japanese Ministry of Health, Labour and Welfare for the commercialization of Epifix in Japan. In April 2021, Kerecis presented its Kerecis Omega3 GraftGuide, an intact fish skin that uniquely manages the challenges of burn healing.

Competitive Landscape

The wound care biologics market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are Organogenesis Inc., Integra Lifesciences, Smith and Nephew, Acell Inc., Osiris Therapeutics, Avita Medical, Solsys Medical, Generex Biotechnology, Mimedx, Skye Biologics among others. The major players are adopting several growth strategies, such as Treatment type launches, acquisitions, and collaborations, which are contributing to the growth of the wound care biologics market globally.

For instance,

  • In July 2022, Biologics Company Tides Medical introduced Artacent AC, a tri-layer skin graft designed to treat complex or difficult-to-treat wounds.
  • In May 2022, MIMEDX received USD 4.6 million in awards department of defense to evaluate PURION-processed Dehydrated Human Amnion Chorion Membrane (DHACM) to advance the treatment of combat casualty wounds and burns.

Zax Healthcare

Overview:

Organogenesis Inc. is a medicine company founded in 1985 and headquartered in the United States. The company offers a portfolio of acellular and bioactive biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine.

Product Portfolio:

PuraPly: It is an antimicrobial wound matrix is an FDA 510(k)-cleared Class II medical device used for the management of various types of wounds, including acute and chronic wound types, such as pressure ulcers, partial and full-thickness wounds, venous ulcers, chronic vascular ulcers, diabetic ulcers, tunneled/undermined wounds, draining wounds, trauma wounds, and first- and second-degree burns.

The global wound care biologics market report would provide access to approximately 65+ market data tables, 65+ figures, and in the range of 200+ (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising incidence of burn injuries
      • 4.1.1.2. Increase research and development activities
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of wound care biologic
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Biological Skin Substitutes*
    • 7.2.1. Synthetic Skin Grafts
    • 7.2.2. Allografts
    • 7.2.3. Xenografts
    • 7.2.4. Introduction
    • 7.2.5. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Topical Agents

8. By Wound Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wound Type
    • 8.1.2. Market Attractiveness Index, By Wound Type
  • 8.2. Chronic Wounds*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 8.2.3. Diabetic Foot Ulcers
    • 8.2.4. Venous Leg Ulcers
    • 8.2.5. Pressure Ulcers
  • 8.3. Acute Wounds
  • 8.4. Surgical Wounds
  • 8.5. Burns
  • 8.6. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Burn Centers
  • 9.4. Ambulatory Surgical Centers
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wound Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wound Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wound Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wound Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wound Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Treatment type Benchmarking

12. Company Profiles

  • 12.1. Organogenesis Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Integra Lifesciences
  • 12.3. Smith and Nephew
  • 12.4. Acell Inc.
  • 12.5. Osiris Therapeutics
  • 12.6. Avita Medical
  • 12.7. Solsys Medical
  • 12.8. Generex Biotechnology
  • 12.9. Mimedx
  • 12.10. Skye Biologics

LIST NOT EXHAUSTIVE

13. Global Wound Care Biologics market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us